We are building a next-gen point-of-care diagnostic platform. Quantitative immunoassays are a workhorse molecular diagnostic technique in central and hospital labs, but take days to perform, are often noisy, and require specialized tools, training, and infrastructure. Current point-of-care alternatives are non-quantitative, application specific, and often unreliable in clinical settings. Our platform can perform any quantitative immunoassay in minutes, is 3x more precise than current methods, does not require specialized disposables, is the size of a shoebox, can be operated by a nurse, and is networked for distributed data harvesting.

These features are critical for bringing high quality, personalized healthcare to clinical environments where time and resources are in short supply. Our first application focus is in combatting the antibiotics crisis. Currently, caregivers struggle to differentiate between bacterial and viral causes of acute respiratory infection (ARI) symptoms. Ou...
We are building a next-gen point-of-care diagnostic platform. Quantitative immunoassays are a workhorse molecular diagnostic technique in central and hospital labs, but take days to perform, are often noisy, and require specialized tools, training, and infrastructure. Current point-of-care alternatives are non-quantitative, application specific, and often unreliable in clinical settings. Our platform can perform any quantitative immunoassay in minutes, is 3x more precise than current methods, does not require specialized disposables, is the size of a shoebox, can be operated by a nurse, and is networked for distributed data harvesting.

These features are critical for bringing high quality, personalized healthcare to clinical environments where time and resources are in short supply. Our first application focus is in combatting the antibiotics crisis. Currently, caregivers struggle to differentiate between bacterial and viral causes of acute respiratory infection (ARI) symptoms. Our technology can give them the data they need in the span of a clinic visit, reducing the massive rates of overtreatment for suspected bacterial ARI’s in the form of antibiotics prescriptions and admissions to the ER.

To date, we have raised seed funds from a number of notable angel, grants, and institutional investors, secured an exclusive license agreement to our core materials technology IP developed by our founders at the University of Southern California, filed a utility patent on this IP, constructed a working prototype of our rapid testing system, and placed a prototype in a collaborator’s laboratory for third-party validation and feedback. We have also assembled a diverse team of leading physicians, industry veterans, and life science experts, creating relationships with multiple major hospitals. Our next milestones are filing several new patent applications and creating first clinical sample datasets.
More information

Advisors

Mitchell Gross
Admin
Mitchell Gross
Richard Bachur
Admin
Richard Bachur